On May 11, 2026, RA Capital Management, L.P., acting through its various affiliated entities, significantly increased its position in Artiva Biotherapeutics, Inc. (NASDAQ: ARTV). The firm acquired 6,510,416 shares of common stock for an estimated total value of $75 million. Each share was purchased at a rate of $11.52.
Detailed Transaction Breakdown
Simultaneous with the common stock acquisition, RA Capital Healthcare Fund, L.P. engaged in a related transaction involving pre-funded warrants. This fund acquired 2,170,138 pre-funded warrants to purchase common stock at a cost of $11.5199 per warrant. These specific instruments carry a nominal exercise price of $0.0001 and are characterized by being immediately exercisable with no set expiration date. However, the exercise of these warrants is constrained by beneficial ownership limitations designed to prevent the fund from holding more than 9.99% of Artiva's total outstanding common stock following any such exercise.
Following these recent moves, the aggregate holdings for the various RA Capital entities are as follows:
- RA Capital Healthcare Fund, L.P.: Indirectly holds 15,203,995 shares of common stock and 2,170,138 pre-funded warrants.
- RA Capital Nexus Fund, L.P.: Indirectly holds 264,571 shares of common stock.
- RA Capital Nexus Fund III, L.P.: Indirectly holds 826,832 shares of common stock.
- Separately Managed Account: Indirectly holds 68,320 shares of common stock.
The reporting parties for these filings include RA Capital Management, L.P., RA Capital Healthcare Fund LP, RA Capital Nexus Fund, L.P., and RA Capital Nexus Fund III, L.P. Key individuals identified in the reporting include Peter Kolchinsky and Rajeev Shah, who serve as managing members of RA Capital Management GP, LLC (the general partner of RA Capital Management, L.P.). Additionally, Laura Stoppel, a Principal at RA Capital Management, L.P., holds a position on the board of directors for Artiva Biotherapeutics.
Financial Position and Market Context
Artiva's current financial profile presents a complex picture of liquidity versus profitability. The company maintains a strong current ratio of 8.16, suggesting that its liquid assets are positioned to significantly exceed its short-term obligations. Furthermore, the balance sheet indicates that Artiva holds more cash than debt. Despite this liquidity, the company remains in a loss position; it reported an EBITDA loss of $89.4 million over the twelve months ending in Q1 2026. Current analyst expectations do not project the company to reach profitability within this calendar year.
The stock has seen extreme movement, characterized by a 412% increase over the last year, though it recently saw a 15% decline from its $10.50 level during the week prior to the report. While some assessments suggest the stock may be overvalued based on fair value metrics, Wall Street analysts maintain an optimistic outlook, with price targets set between $23 and $41.
Clinical Developments and Capital Raising
Artiva is currently navigating several pivotal corporate events. The company recently announced the pricing of a $300 million stock offering intended to generate gross proceeds through the sale of common stock and pre-funded warrants, with an expected closing in May 2026. This comes on the heels of positive clinical data regarding its AlloNK therapy. In trials involving rheumatoid arthritis patients, 71% of refractory patients achieved an ACR50 response after six months of follow-up. Notably, no patients required new immunomodulatory agents or experienced a relapse by the designated data cutoff point.
These clinical results, which stemmed from both investigator-initiated and company-sponsored Phase 2a basket trials for B-cell autoimmune diseases involving 21 patients, have influenced analyst sentiment. H.C. Wainwright raised its price target to $35 while maintaining a Buy rating, and Cantor Fitzgerald reiterated an Overweight rating with a $10 price target.